HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tiratricol-Containing Products Not Dietary Supplements - U.S. Judge

This article was originally published in The Tan Sheet

Executive Summary

Tiratricol cannot be marketed as a dietary supplement because it has been the subject of an investigational new drug application since 1990, a Cape Girardeau, Mo. federal judge has ruled in an FDA enforcement action against Syntrax Innovations.

You may also be interested in...



Syntrax LipoKinetix Liver AERs Necessitate Product Removal – FDA

LipoKinetix should be withdrawn from the market due to reports linking the weight-loss supplement to "at least six" cases of serious liver injury, FDA states in a 1Nov. 19 letter to Chaufee, Mo.-based Syntrax Innovations

Tiratricol

ATF Fitness recalling BioPharm T-Cuts supplement containing ingredient deemed to be a "potent thyroid hormone" that may cause heart attacks, strokes. Oakmont, Penn.-based ATF distributed 90-count bottles of T-Cuts (made by BioPharm) nationwide through mail order, health food stores and gyms. Approximately 400 bottles are affected by recall. FDA actions against tiratricol products culminated in recent decision by Missouri federal judge that ingredient cannot be marketed as supplement because it has been the subject of an IND since 1990 (1"The Tan Sheet" March 12, p. 10)

Triax Weight Loss Supplement Distribution Halted At FDA's Request

The Missouri Department of Health has barred dietary supplement distributor Syntrax Innovations from selling its on-hand supply of a weight loss nutritional supplement due to FDA concerns the product is an unapproved new drug.

Related Content

Topics

UsernamePublicRestriction

Register

RS132427

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel